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Abstract: Clinical data show a strong correlation between tobacco and alcohol use and the development of oral squamous 
cell carcinoma (SCC). While this association implies that the oral mucosa actively metabolizes carcinogens, there is little 
information which depicts the carcinogen metabolizing enzymes within the oral cavity. Glutathione S-transferases (GSTs) 
primary function is to detoxify carcinogens by increasing their water solubility, GSTs represent key carcinogen metaboliz-
ing enzymes. Notably, individuals with a null phenotype for certain GST isoforms are at an increased risk to develop cancer. 
This study investigated the function and distribution of GSTs in human oral tissues. Our results from this pilot study showed 
a trend towards higher GST activities in SCC tissues relative to normal mucosa. Also, relative to normal tissues, the SCC 
and epithelial dysplasia samples showed a more intense and uniform GST intracellular distribution. GST activities are 
increased in many high grade cancers. Similarly, our data suggest that GST upregulation occurs in at least a subset of 
precancerous and malignant oral lesions.
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Introduction
The development of oral SCC correlates strongly with the carcinogen exposure which occurs during 
tobacco and ethanol use (Neville et al. 2002; La Vecchia et al. 1997). Furthermore, development of oral 
SCC is thought to be a multistep process, with the initial phase of carcinogenesis entailing enzymatic 
bioactivation of the pro-carcinogen, followed by the covalent binding of the activated carcinogen to 
nuclear DNA (Harris, 1991). Although clinical evidence strongly supports the premise that the oral 
mucosa is actively engaged in carcinogen metabolism, little is known regarding the distribution and 
activities of carcinogen metabolizing i.e. Phase I and II enzymes, within the oral cavity.
Exposure to xenobiotics, such as tobacco associated carcinogens, induces expression and function 
of both Phase I (e.g. cytochrome P450s) and Phase II (e.g. GSTs) enzymes (Guengerich, 1991; Hayes 
et al. 1995). Although the microsomally located P450s are generally considered chemical detoxiﬁ  ers, 
the P450s catalyze oxidation reactions that have the potential for carcinogen bioactivation. Glutathione 
S-transferases (GSTs) are a superfamily of Phase II enzymes which are present in either a soluble (Alpha, 
Mu, Pi, and Theta) or membrane-bound (microsomal), state (Hayes et al. 1995). Speciﬁ  cally, GSTs 
catalyze the conjugation of electrophilic, hydrophobic carcinogens with the reduced thiol of the gluta-
thione (GSH) tripeptide; a detoxiﬁ  cation reaction that increases the water solubility and facilitates 
excretion in the urine (Bongers et al. 1995). Furthermore, as GSTs also detoxify carcinogens which 
have been bioactivated by Phase I enzymes (Wilce et al. 1994), the relative intracellular distribution of 
P450’s and GSTs may be critical in determining the extent of DNA damage following carcinogen 
exposure.160
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Recently, studies have begun to characterize 
oral mucosal GST activities. Saroja et al. demon-
strated that relative to histologically normal 
mucosa, tissue derived from Stage IV oral SCC 
tissues demonstrate signiﬁ  cantly higher levels of 
total GST activities (Saroja et al. 1999). Similarly, 
Rawal et al. determined that relative to corre-
sponding adjacent histologically normal tissues, 
oral SCC samples possess signiﬁ  cantly higher 
GST levels (Rawal et al. 1999). Notably, neither 
of these previous reports determined GST expres-
sion in precancerous oral lesions. In addition, 
although these previous studies report higher GST 
functional activities in SCC relative to non neo-
plastic oral mucosal samples, these data do not 
refute the possibility of a biphasic role for GSTs 
in oral carcinogenesis. Low GST levels could 
enhance the mutation-associated initiation phase 
of carcinogenesis, while the acquisition of 
increased GST function by oral SCC lesions could 
facilitate tumor cell survival during cancer pro-
gression. This premise is supported by the fact that 
highly progressed tumors frequently overexpress 
cytoprotective enzymes, including GSTs, which 
partially account for some of their resistance to 
various chemotherapeutic agents (Saroja et al. 
1999; Rawal et al. 1999).
Although characterizing the distribution of 
Phase I and II enzymes within the oral cavity is 
of scientiﬁ  c interest, these data could also directly 
impact translational applications regarding che-
mopreventive agent selection and use. The pur-
pose of this study was to evaluate the cellular 
distribution of three GST isoforms (GST A1-1, 
GST M2-2, and GST P1-1) in normal, dysplastic, 
and oral SCC tissue. These speciﬁ  c isoforms were 
selected for evaluation due to the recognized 
association between polymorphisms in these 
isoforms and the development of human epithelial 
origin cancers (Their et al. 2003). GST A1-1 is 
the most abundant GST isoform (Ping et al. 
2006). The GST Alpha isoform has been shown 
to confer protection against products of lipid 
peroxidation, such as α,β-unsaturated aldehydes 
that can be produced in response to various oxi-
dative stimuli, for example, chronic alcohol 
exposure (Alin et al. 1985; Ingelman-Sundberg 
et al. 1984). In previous studies GST M2-2 has 
been shown to be effective in reducing benzo[a]py-
renedioleepoxide (BPDE) induced cellular DNA 
damage. BPDE represents a highly active metab-
olite of benzo[a]pyrene (B(a)P), a significant 
tobacco-associated carcinogen that can form DNA 
adducts leading to (B(a)p)-induced neoplasia 
(Shinozaki et al. 1998; Lee et al. 1998; Weng et al. 
2005). GST-P1 is the isoform that is most associ-
ated with the detoxiﬁ  cation of tobacco-associated 
carcinogens and it is also the most abundant GST 
enzyme in the head and neck area (Mulder et al. 
1995). In addition, GST functional enzymatic 
analyses were conducted on both normal and SCC 
derived tissues. Our results suggest that at least 
a subset of premalignant and malignant oral 
lesions undergoes a biochemical adaptation 
resulting in increased GST levels.
Materials and Methods
Oral mucosal tissue samples
All tissues used for these studies were obtained in 
compliance with the stipulations of The Ohio State 
University’s Institutional Review Board for use of 
human tissues. Ten normal oral mucosal samples 
were obtained from patients undergoing elective 
oral surgical procedures at The Ohio State Univer-
sity College of Dentistry. At the surgical appoint-
ment, social and medical histories were obtained 
from the tissue donors, and clinical assessments 
(presence or absence of inﬂ  ammation or surface 
ulceration), made of the tissue sites. All of the 
patients from which normal samples were obtained 
had noncontributory medical histories. One patient 
reported an allergy to penicillin. Subsequent to 
obtaining the necessary consent, normal samples 
were collected under local anesthesia at the time 
of the patient’s elective oral surgical procedure.
Fourteen samples of oral SCC were obtained 
from patients undergoing tumor resections at The 
Ohio State University James Cancer Hospital through 
The Ohio State University Tissue Procurement 
Network. Medical and social histories were 
provided by Tissue Procurement Network for the 
SCC tissue donors. Oral SCC samples were 
collected by tissue procurement services from 
patients undergoing surgical excision of their 
neoplasm. Other than their diagnosis of oral SCC, 
patients exhibited an otherwise unremarkable 
medical history with no previous history of 
radiation or chemotherapy treatments. Surgical 
specimens were received in Modified Eagle’s 
Medium transport media.
Normal and SCC samples were processed in the 
following manner: a representative sample was 161
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fixed for two hours in 10% neutral buffered 
formalin, followed by routine tissue processing 
and parafﬁ  n embedding. The remainder of the 
sample was snap frozen (−80 °C) until preparation 
of cytosolic extracts. Routine hematoxylin and 
eosin sections were prepared of all tissue samples 
to conﬁ  rm the diagnosis, and to assess extent and 
character of any inflammatory cell infiltrate. 
Following microscopic conﬁ  rmation of the clinical 
diagnosis, multiple 4 µm sections were prepared 
and placed on Superfrost/Plus slides (Fisher 
Scientiﬁ  c, Pittsburgh, PA) for immunohistochemical 
analyses.
In addition, 10 archival samples of formalin-
ﬁ  xed oral epithelial dysplasia (samples included 
mild, moderate, and severe dysplasia which had 
undergone a similar short-duration formalin ﬁ  xa-
tion) were prepared for immunohistochemical 
analyses.
Immunohistochemistry
Sections of normal, dysplastic, and SCC tissue 
were deparafﬁ  nized, and hydrated using standard 
techniques. Peroxidase activity was then blocked 
with 0.3% H2O2 in methanol for 30 minutes at 
room temperature, followed by a rinse with phos-
phate buffered saline (PBS). Following incubation 
with normal goat blocking serum for 20 minutes 
(Vector Laboratories, Burlingame, CA), and 
avidin and biotin blocking agents for 15 minutes 
each (Vector Laboratories, Burlingame, CA), 
sections were incubated with three GST antibod-
ies (Vector Laboratories, Burlingame, CA.) GST 
A1-1 (1:100), GST M2-2 (1:200), and GST P1-1 
(1:100) overnight at 4 °C in a humidiﬁ  ed cham-
ber. Sections were then incubated with biotinyl-
ated secondary antibody for 30 minutes (Vector 
Laboratories, Burlingame, CA), rinsed with 
PBS, and then incubated with the VECTASTAIN 
ABC Elite kit for 30 minutes (Vector Laborato-
ries, Burlingame, CA). Next, the slides were 
rinsed with PBS, incubated with DAB 
(3,3’-diaminobenzidine) substrate (Vector 
Laboratories, Burlingame, CA), rinsed in water, 
counterstained with hematoxylin, dehydrated, 
and mounted with Permount (Fisher Scientiﬁ  c, 
Pittsburgh, PA.). The isotypic negative controls 
received identical handling, with the exception 
that pre-immune blocking serum (Vector Labo-
ratories, Burlingame, CA) was used instead of 
primary antibody.
Preparation of cytosols for functional 
GST analyses
Tissue fragments (10–100 mg) were thawed and 
homogenized on ice in 5 volumes of homogeniza-
tion buffer (0.05 M Tris-HCl, 1.15% KCl, and 0.1 
mM phenylmethylsulfonyl ﬂ  uoride (PMSF), pH 
7.4 using a Polytron homogenizer (Kinnematica, 
Switzerland). The homogenates were centrifuged 
at 150,000 
× g at 4 
 °C for 1 hour. The volume of 
the cytosolic extract was recorded, and a represen-
tative aliquot taken for protein determination, and 
the supernates stored at -80
 °C until analysis of 
GST functional activity was performed.
Determination of total GST functional 
activity
The method of (Habig et al. 1974) was used to 
determine tissue total GST functional activity. 
GST activity was spectrophotometrically deter-
mined (Beckman DU 7400 equipped with a 
Peltier temperature regulator) by measuring the 
formation of the conjugation product of chloro-
dinitrobenzene (CDNB) and reduced GSH 
(Sigma Biochemical, St. Louis, MO) under the 
following assay conditions: 340 nm, pH 6.5, 1 
mM reduced glutathione (GSH), 25 °C, 1.0 mM 
CDNB. With every assay, a concurrent ﬁ  ve point 
standard curve (0.1, 0.5, 1.0, 5.0, 10.0 units/ml) 
was conducted, and specimen GST activities 
remained within the linear range of the standard 
curve. GST activity is expressed as units/mg 
protein, with 1 unit of GST deﬁ  ned as the enzy-
matic concentration that will conjugate 1.0 µmole 
of CDNB with reduced GSH per minute at pH 
6.5 at 25 °C. CDNB is a universal substrate for 
Alpha, Mu and Pi GST isoforms. Results are 
expressed as units of activity per mg of sample 
protein.
Protein determination
Sample protein levels were determined by using 
the BCA (bicinchoninic acid) Protein Assay Kit 
using bovine serum albumin as the standard protein 
(Pierce, Rockford, IL).
Western blotting to conﬁ  rm speciﬁ  city 
of GST antibodies
Western blot analysis, using standard techniques, 
was performed to determine if cross-reactivity 162
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existed among the GST Alpha, Mu, and Pi antibodies. 
GST Alpha, Mu, and Pi proteins (Sigma Chemical 
Company, St. Louis, MO) were applied to sodium 
dodecyl sulfate polyacrylamide gels (SDS-
PAGE), 30 µg of protein per well, which was run 
at 120 V for 1–2 hours. Following electrophoresis, 
the proteins were transferred to a Hybond-P 
PVDF membrane by placing the SDS-PAGE in 
direct contact with the PVDF membrane, which 
was then run at 100 V for 1 hour in a transfer 
buffer. Nonspecific binding of antibody was 
blocked with 5% nonfat milk in PBS + 0.5% 
Tween-20 (PBS-T) for 1 hour. Gels were then 
incubated with each of the three primary antibod-
ies (GST α, µ, and π) in 5% nonfat milk in PBS-T 
overnight at 4 
oC. This was followed by incuba-
tion for 1 hour with a goat anti-rabbit secondary 
antibody conjugated to horseradish peroxidase in 
5% nonfat milk in PBS-T at a dilution of 1:15,000. 
The gels were then incubated for 1 minute in 
detection solution at room temperature. Excess 
detection solution was drained from the blots. 
They were subsequently exposed to Kodak ﬁ  lm 
in a darkroom, which was later developed to allow 
for visualization of the bands.
Statistical analysis
A Mann-Whitney rank sum test was utilized to 
assess any signiﬁ  cance in the observed GST func-
tional activities between normal and oral SCC 
mucosa.
Results
Patient data and social history
Of the ten patients from whom samples of normal 
oral mucosa were obtained, the average age was 
41 yrs. with a standard deviation of 20.3 yrs., and 
a 3:2 male to female ratio. None of the patients 
reported a personal or family history of cancer. 
In terms of race, 9 of 10 normal subjects were 
Caucasian and one was African-American. Four 
of the subjects had a signiﬁ  cant smoking history, 
while none had a positive history of alcohol use. 
Dysplastic tissue samples were obtained from a 
variety of sites including vestibule, lip, tongue, 
palate, ﬂ  oor of mouth, and buccal mucosa. Most 
patients did not report a personal or family his-
tory of cancer. The average age was 53 yrs. with 
a standard deviation of 14.4 yrs., and a 7:3 male 
to female ratio. Similar to the patient group from 
whom normal oral mucosa was obtained, 9 of 10 
patients in the dysplasia group were Caucasian 
and one was African-American. Most (70%) did 
have a history of smoking however, a signiﬁ  cant 
alcohol history was not observed. Oral SCC tis-
sue was harvested from a variety of sites includ-
ing tongue, palate, tonsil, pharynx, buccal 
mucosa, and neck. The average age of oral SCC 
patients was 55 yrs. with a standard deviation of 
13.5 yrs., and a 3:2 male to female ratio. All of 
the oral SCC patients were Caucasian. Most 
patients reported no prior personal or family his-
tory of cancer however, 67% had reported a 
signiﬁ  cant smoking history. Likewise, 50% of 
the patients had a signiﬁ  cant alcohol consumption 
history.
Immunohistochemical analysis
of GST Alpha, Mu, and Pi
In order to verify that there was no cross-
reactivity between the GST antibodies, a Western 
Blot was performed (Fig. 1). The immunoblot 
results demonstrate a lack of cross-reactivity 
and show that the GST antibodies (A1-1), (M2-2), 
and (P1-1) were specific for their respective 
antigen.
Immunoreactivity of parrafﬁ  n-embedded oral 
tissue using GST (A1-1), (M2-2), and (P1-1) 
polyclonal antibodies showed differential 
expression of these proteins in normal, dysplas-
tic, and oral SCC tissues. Representative oral 
tissue immunohistochemical sections are shown 
in (Figs. 2–4). A common finding among all 
tissues analyzed was greater staining, corre-
sponding to increased GST expression in the 
surface epithelial cells relative to connective 
tissues. The surface epithelium of normal tissues 
demonstrated a light to moderate GST staining 
for the Alpha, Mu, and Pi isoforms; findings that 
are indicative of a low level of expression of 
each of the three GST proteins that were inves-
tigated. In normal epithelium, GST proteins 
appear to be localized primarily within the 
cytoplasm of cells in the basal layer, with 
decreased expression apparent in the more dif-
ferentiated epithelial cells. In contrast, dysplas-
tic oral tissues (regardless of histologic grade) 
did not manifest the differentiation-associated 
GST expression. Dysplastic samples showed 
moderate expression of GST proteins throughout 163
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Figure 1. Western blot analysis for GST A1-1, M2-2, and P1-1 demonstrating GST antibody speciﬁ  city.
the epithelium. Intense expression of GST 
Alpha, Mu, and Pi was observed in all oral SCC 
tissues. Well-differentiated tumors demonstrated 
moderate expression of all three GST isoforms, 
with greater expression in the basal cells of the 
invading epithelial islands, similar to that observed 
in normal mucosa. Greatest GST expression, 
however, was detected in the highest grade 
tumors, corresponding to 5/14 or 36% of oral 
SCC samples. Also unique to the SCC samples 164
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was preferential expression of the GST π 
isoform.
GST enzyme activity
Cytosolic preparations from both normal and oral 
SCC samples were prepared for the determination 
of the units of GST enzymatic activity per mil-
ligram of protein (GST U/mg) (Table 1). We did 
not discern any correlations between GST func-
tional activities and the presence or absence of 
inﬂ  ammation, or use of either alcohol and/or 
tobacco.
Comparison of the GST enzymatic activities of 
normal and SCC oral mucosa revealed a trend 
toward higher GST enzyme activity for the SCC 
samples (Table 1). In addition, consistent with the 
recognized extensive heterogeneity in human 
Phase II enzyme activities, a wide range of GST 
functional activities was detected in our specimens. 
While the histologically normal tissues demon-
strated a 93 fold difference in GST activities, an 
even greater range (107 fold difference in GST 
activities) was detected among the SCC samples. 
In comparing the mean GST activities of the nor-
mal and oral SCC samples, a 2.5 fold increase in 
mean GST activity was noted in the SCC speci-
mens. Results from a Mann-Whitney rank sum test 
for the comparison of GST enzymatic activities of 
normal and SCC oral mucosa did not reveal a 
statistically signiﬁ  cant difference in these values 
at the p = 0.05 level of signiﬁ  cance.
Discussion
The GSTs are part of a complex supergene family 
of detoxiﬁ  cation proteins which are involved in 
conjugation reactions which increase the water 
solubility of electrophilic compounds, thus facili-
tating their elimination (Hayes et al. 1995). GSTs 
exist in ﬁ  ve main classes: Alpha, Mu, Pi, Theta, 
and microsomal or membrane-bound. The GSTs’ 
cytoprotective effects extend beyond primary 
carcinogen metabolism. In the event that a 
procarcinogen is bioactivated to a carcinogen by 
phase I enzymes, such as the cytochrome P450s, 
GSTs can subsequently detoxify the agent prior to 
cell damage.
It is well known that GST polymorphisms can 
modify the gene expression of GST proteins. Pre-
vious studies have been conducted to investigate 
the role of GST null genotypes, speciﬁ  cally the 
GST M1-1 null genotype, and its relationship to 
the risk for such cancers as lung, bladder, and oral 
SCC (Rebbick, 1997). The prevalence of the GST 
M1-1 null genotype averages 50% in various 
Figure 2. GST A1-1 expression in normal oral mucosa (100X). Mild 
GST expression is primarily localized to the cytoplasm of cells within 
the basal layer.
Figure 3. GST P1-1 expression in dysplastic oral mucosa (100X). 
Moderate GST expression is demonstrated throughout the entire 
epithelium.165
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populations including persons of European, His-
panic, and Asian descent. In persons of African 
descent the prevalence of the GST M1-1 null 
genotype is about 40%. Previous studies have 
demonstrated that the GST M1-1 null genotype 
does not impart a signiﬁ  cantly increased risk for 
the development of oral SCC (Park et al. 1997; 
Hung et al. 1997; Jourenkova-Mironova et al. 
1999; Gronau et al. 2003). Another study investi-
gated the role of GST M1-1 polymorphisms and 
risk for oral SCC in African-Americans and 
Caucasians. In Caucasians the GST M1-1 null 
genotype revealed similar results imparting no 
increased risk for oral SCC. Conversely, in African-
Americans, the GST M1-1 null genotype has been 
shown to signiﬁ  cantly increase the risk for oral 
cancer (Park et al. 2000).
Our results from this pilot study showed 
minimal expression of all three GST isoforms, GST 
(A1-1), (M2-2), and (P1-1) in normal mucosa, with 
staining largely restricted to the cytoplasm and 
perinuclear regions of the basal cells. Most of 
the normal mucosal samples for this study were 
gingival (8/10) while the remaining samples were 
obtained from alveolar mucosa. The normal 
mucosal samples were harvested from patients 
undergoing elective oral surgical procedures. Some 
patients were undergoing surgery for third molar 
extractions while others were presenting for 
biopsies of lesions involving the gingiva or alveolar 
mucosa.
In contrast, there was markedly greater staining 
intensity observed in both dysplastic and SCC tis-
sues. Six oral SCC samples were harvested from 
the tongue, two each were from the pharynx and 
cervical lymph nodes, with one each being har-
vested from the mandibular alveolar mucosa, buc-
cal mucosa, soft palate, and tonsil.
Unlike the normal tissues, GST positive staining 
was observed throughout the epithelium in the 
dysplastic and SCC samples. This observation was 
most apparent with regard to the GST Pi isoform. 
Table 1. GST functional activities in normal and SCC tissues.
Normal mucosa  GST activity  Oral SCC + site  Histologic grade  GST activity 
+ site  (U/mg)      (U/mg)
1 Gingiva  0.55  1 Tongue  Well differentiated  0.24
2 Gingiva  3.88  2A Tongue  Well differentiated  0.70
3 Gingiva  1.44  2B Lymph node  Well differentiated  0.77
   with  tumor 
4 Gingiva  2.50  2C Tongue  Well differentiated  1.25
5 Alveolar mucosa  4.67  3 Tonsil  Well differentiated  0.61
6 Gingiva  0.18  4 Tongue  Moderately differentiated  0.70
7 Gingiva  0.31  5 Cervical lymph  Moderately differentiated  4.71
   node  with  tumor 
8 Alveolar mucosa  0.05  6 Mandibular mucosa  Well differentiated  0.83
9 Gingiva  0.23  7 Soft palate  Well differentiated  25.68
10 Gingiva  0.09  8 Tongue  Moderately differentiated  7.27
    9 Pharynx  Moderately differentiated  0.72
    10 Pharynx  Well differentiated  1.49
    11 Buccal mucosa  Well differentiated  1.76
   12  Tongue  Moderately  differentiated  0.77
Normal tissue mean ± s.e.m.  Oral SCC tissue mean ± s.e.m.
1.39 ± 0.54    3.43 ± 1.93
Figure 4. GST P1-1 expression in well-differentiated oral SCC (40X). 
Moderate GST expression is observed to be more intense within the 
basal cells of the invading epithelial islands.166
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Notably, GST Pi is the predominant isoform pres-
ent in tissues of the gastrointestinal tract, lung, and 
erythrocytes (Tsuchida et al. 1989; Moscow et al. 
1989). Relevant to our results, overexpression of 
the GST Pi isoform has been found in a variety of 
premalignant and malignant epithelial lesions. 
Previous studies have noted an increased expression 
of GST Pi in human premalignant and malignant 
tissues of the colon, kidney, and lung when com-
pared to their surrounding normal counterparts 
(Chasseaud, 1979; Kodate et al. 1986; Di Ilio et al. 
1987; Di Ilio et al. 1988). Our results also show 
greater staining intensity of GST Alpha, Mu, and 
Pi in more poorly differentiated relative to well-
differentiated SCC tumors. Our pilot study data 
compare favorably to ﬁ  ndings reported by Rawal 
et al. who observed that the more poorly differen-
tiated SCC tumors possessed higher GST activities 
(Rawal et al. 1999). Several studies have provided 
mechanistic insights into how increased GST 
activities could provide a survival advantage to 
human cancers (Paumi et al. 2001; Goto et al. 
2001). These selective survival advantages 
included rapid detoxiﬁ  cation and transport of che-
motherapeutic agents, as well as prevention of 
chemotherapeutic agent mediated DNA mutations 
(Harbottle et al. 2001; Sato et al. 1999).
Our data, which demonstrate large ranges in GST 
activities among the human donors, are consistent 
with the recognized heterogeneity in Phase I and II 
enzyme function in humans (Nebert et al. 1996). 
While our functional assays only showed a tendency 
towards higher GST function in SCC tumors, our 
immunohistochemistry results conﬁ  rmed higher 
GST expression of all three isoforms evaluated in 
both the epithelial dysplasia and SCC lesions. Our 
results also suggest that GST expression manifests 
both a cell type and a growth state speciﬁ  city, with 
highest levels of expression detected in proliferating 
epithelial cells. Because DNA synthesis is one of 
the most energetically costly cell processes, there is 
a concurrent increase in cellular oxidative metabo-
Table 2. GST functional activities, age, sex, smoking, and signiﬁ  cant alcohol history in normal and SCC oral 
tissues.
Normal mucosa
Age/Sex  GST activity (U/mg)  Smoking history  Alcohol history
46/M 0.55  Yes  (1ppd/15yrs.)  None
23/F 3.88  None  None
50/M 1.44  None  None
22/M 2.50  Yes  None
78/F 4.67  None  None
69/M 0.18  None  None
22/M 0.31  None  None
51/F 0.05  Yes  (1ppd/10yrs.)  None
22/M 0.23  None  None
22/F 0.09  Yes  (1pack/week)  None
Oral SCC
Age/Sex  GST activity (U/mg)  Smoking history  Alcohol history
54/F 0.24  None  None
50/M  0.70  Yes (60 pack yr.)  Heavy use
50/M  0.77  Yes (60 pack yr.)  Heavy use
50/M  1.25  Yes (60 pack yr.)  Heavy use
40/F  0.61  Yes (24 pack yr.)  Weekends only
54/F 0.70  None  None
30/M 4.71  Yes  3  drinks/day
42/F 0.83  None  None
66/M  25.68  Yes (42 pack yr.)  Previous alcohol abuse
65/M 7.27  None  None
56/M  0.72  Yes (80 pack yr.)  Quit 2 years prior
50/M 1.49  Yes  None
78/M 1.76  Yes  None
74/M 0.77  Yes  None167
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lism and subsequent generation of reactive oxygen 
species and electrophilic molecules. Therefore, the 
observed increased GST expression in cells and 
tissues with high proliferation indices likely reﬂ  -
ects a cytoprotective, reactive species and electro-
phile scavenging, cellular response.
The role of Phase I and II enzymes in either the 
induction or prevention of oral cancer is complex 
and entails interactions that include extent and type 
of carcinogen exposure, relative distribution and 
function of Phase I and II enzymes, and individual 
capacity to upregulate detoxiﬁ  cation pathways. As 
GSTs serve a cytoprotective function, one could 
speculate that highest levels would be present in 
healthy, normal tissues. Therefore, detection of 
increased GST expression in premalignant and 
malignant lesions as noted in our and others’ studies 
may initially appear counter-intuitive. These collec-
tive data, however, imply that GST overexpression 
may facilitate cellular transformation by provid-
ing survival advantages in at least a subset 
of premalignant and malignant oral lesions. 
Recognition of unique biochemical features, 
such as GST overexpression, could facilitate subse-
quent development and selective targeting of 
chemopreventive and chemotherapeutic agents for 
premalignant and malignant oral lesions.
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